Welcome to our dedicated page for BioAge Labs SEC filings (Ticker: BIOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
BioAge Labs, Inc. ownership disclosure: this Schedule 13G/A Amendment No. 1 reports that affiliated Khosla entities and Vinod Khosla collectively hold shared beneficial interests totaling 1,798,702 shares, representing 4.0% of common stock. The percentages are calculated using 44,452,734 shares outstanding as of May 1, 2026.
The filing states the change in reported percentages is solely due to the updated outstanding share count from the issuer's Form 10-Q; the reporting persons assert no other ownership changes and voluntarily report that ownership decreased below 5%.
BioAge Labs, Inc. Schedule 13G/A amendment shows Cormorant Asset Management and Bihua Chen report beneficial ownership of 2,890,605 shares, representing 6.51% of common stock. The filing cites 44,379,753 shares outstanding as of March 19, 2026. The statement is a joint filing and notes shared voting and dispositive power over the reported shares.
BioAge Labs, Inc. reported first quarter 2026 results, highlighting pipeline progress and a larger operating loss as it invests in development. Collaboration revenue was $2.8 million versus $1.5 million a year earlier, driven by higher work under its Novartis collaboration.
Research and development expenses rose to $20.4 million and general and administrative expenses to $7.7 million, leading to a net loss of $22.3 million or $0.52 per share, compared with a $12.9 million loss in 2025. The company closed an upsized follow-on public offering with gross proceeds of about $132.3 million and ended March 31, 2026 with $384.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations through 2029.
BioAge reported positive Phase 1 data for its oral NLRP3 inhibitor BGE-102, showing median 86% reductions in hsCRP at 60 mg and 120 mg once-daily doses and a favorable safety profile. It plans to start a Phase 2 cardiovascular risk study and a Phase 1b/2a diabetic macular edema trial for BGE-102 in mid-2026, while advancing APJ agonist programs toward an initial IND filing by year-end 2026.
BlackRock, Inc. reported beneficial ownership of 2,236,460 shares of BioAge Labs, Inc. common stock, representing 5.03% of the class as of 03/31/2026. The filing shows sole voting power over 2,208,192 shares and sole dispositive power over 2,236,460 shares. The Schedule 13G was signed on 04/27/2026 by Spencer Fleming as Managing Director and states the holdings reflect aggregated Reporting Business Units of BlackRock.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein exercised stock options for 3,542 shares of common stock at $4.38 per share. Following the exercise, he directly holds 36,575 common shares and 155,833 stock options, which vest in equal monthly installments through their February 17, 2035 expiration.
BioAge Labs, Inc. is holding its 2026 virtual annual stockholder meeting on June 10, 2026 at 12:00 p.m. Eastern Time. Stockholders of record as of April 16, 2026, when 44,397,817 common shares were outstanding, may vote online, by telephone, or by mail.
Stockholders will vote on electing three Class II directors to three-year terms and on ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board unanimously recommends voting FOR both proposals.
The company describes its corporate governance structure, committee composition, director independence and compensation, and executive pay. In 2025, CEO Kristen Fortney received a $600,000 salary, a $330,000 cash bonus, and option awards valued at $1,941,390. BioAge also highlights its emerging growth and smaller reporting company status and recently adopted clawback and updated insider trading policies.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and then sold the resulting shares. On April 1, 2026, he exercised options covering 8,820 shares of common stock at strike prices of $4.11 and $6.57 per share.
The same day, he sold 8,820 shares of common stock at $17.81 per share in an open-market transaction, leaving 0 shares of common stock held directly after the sale. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
BIOA Rule 144 notice: The filing lists proposed and recent sales of Common stock under Rule 144. It shows three reported sales by Paul Rubin of 7,433 shares each on 01/02/2026, 02/02/2026, and 03/02/2026 with dollar proceeds reported for each sale. The filing also lists securities to be sold on 04/01/2026 connected to options granted on 07/01/2020 and 05/29/2022.